Cutaneous Squamous Cell Carcinoma - Updates in Immunotherapy presented by Dr. Butler MD

Watch a live recording of our recent webinar with Dr. Marcus Butler, MD on the "Evolving Landscape of Cutaneous Squamous Cell Carcinoma Treatment: Updates on Immunotherapy Treatment"

Cutaneous Squamous Cell Carcinoma (cSCC) is the second most common form of skin cancer in Canada, with an estimated 16,000+ patients nationally. It is forecasted that anywhere from 200-700 of these patients have locally advanced or metastatic cSCC.

This livestreaming program targets surgeons from a number of specialties that are involved in the treatment of cSCC patients, to advise on a new, recently approved curative treatment. Cemiplimab is a fully-human monoclonal antibody that is the first and only biologic immunotherapy treatment specifically approved and available for adult patients with metastatic or locally advanced cSCC.

You Are Not Alone - cSCC patient support

Download a copy of our cSCC patient guide - Helping You Understand cutaneous Squamous Cell Carcinoma (cSCC) A Patient Guide

cSCC Treatment information

About Dr. Marcus Butler
Dr. Marcus Butler, MD
Medical Oncologist, Princess Margaret Cancer Centre,
University Health Networ

Melanoma Network of Canada
1.877.560.8035

Facebook

Twitter

Instagram

[jeffsmithist]

Note that 85yo was going to be assisted in dying by the medical Dr. Later received care and was doing well. Don’t let the Dr help you DIE